Bristol-Myers Squibb Co.

NYSE:BMY  
58.35
+0.65 (+1.13%)
4:00:02 PM EDT: $58.36 +0.01 (+0.02%)
Products

U.S. FDA Accepts Bristol Myers Squibb’s Applications For Opdivo + Yervoy And Opdivo + Chemotherapy For Unresectable Advanced, Recurrent Or Metastatic Esophageal Squamous Cell Carcinoma

Published: 09/27/2021 11:35 GMT
Bristol-Myers Squibb Co. (BMY) - U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent Or Metastatic Esophageal Squamous Cell Carcinoma.
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy for Unresectable Advanced, Recurrent Or Metastatic Esophageal Squamous Cell Carcinoma.
Bristol-myers Squibb Co - U.S. Food and Drug Administration Assigned a Target Action Date of May 28, 2022.
Bristol-myers Squibb Co - Applications Based on Phase 3 Checkmate -648 Trial.